Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.

Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.

Disclosed are peptidomimetic macrocycles comprising a helix, such as an alpha helix, and methods of using such macrocycles for the treatment of disease such as cancer. In other aspects, the peptidomimetic macrocycle comprises an ,-disubstituted amino acid, or may comprise a crosslinker linking the -positions of at least two amino acids or at least one of said two amino acids may be an ,-disubstituted amino acid. Further included is the targeting of components of the Wnt signaling pathway such as the Tcf4-/3-catenin complex.

Disclosed are peptidomimetic macrocycles comprising a helix, such as an alpha helix, and methods of using such macrocycles for the treatment of disease such as cancer. In other aspects, the peptidomimetic macrocycle comprises an ,-disubstituted amino acid, or may comprise a crosslinker linking the -positions of at least two amino acids or at least one of said two amino acids may be an ,-disubstituted amino acid. Further included is the targeting of components of the Wnt signaling pathway such as the Tcf4-/3-catenin complex.

The present invention relates to cyclic peptides mimetics of the C-terminal binding domain of TSP-1. The present invention also relates to the use of these cyclic peptides as agonists of CD47 and their ability to trigger programmed cell death (PCD). The present invention further relate to a pharmaceutical composition for use in the treatment of diseases associated with defects in PCD such as cancers and immunological disorders (including chronic inflammation) and comprising at least one cyclic peptide according to the invention.

The present invention relates to cyclic peptides mimetics of the C-terminal binding domain of TSP-1. The present invention also relates to the use of these cyclic peptides as agonists of CD47 and their ability to trigger programmed cell death (PCD). The present invention further relate to a pharmaceutical composition for use in the treatment of diseases associated with defects in PCD such as cancers and immunological disorders (including chronic inflammation) and comprising at least one cyclic peptide according to the invention.

This patent document provides novel compounds as warheads for therapeutic or diagnostic agents. Advantages of the agents modified with the warheads include low off-target conjugation and minimized immunogenicity due to the reversible covalent bonding between the warheads and the targets.

This patent document provides novel compounds as warheads for therapeutic or diagnostic agents. Advantages of the agents modified with the warheads include low off-target conjugation and minimized immunogenicity due to the reversible covalent bonding between the warheads and the targets.

Provided is a production method of a polypeptide in which expressing a polypeptide as a tagged polypeptide is included, the method including expressing the tagged polypeptide from a nucleic acid containing a base sequence encoding a tag consisting of an amino acid sequence set forth in SEQ ID NO: 1, which is arranged immediately after a start codon, and a base sequence encoding a polypeptide that is arranged in-frame downstream of the base sequence encoding the tag,

SEQ ID NO: 1: Val-Lys-Lys-(Xaa)n. (Xaa)n is a chain of n pieces of any amino acids, where n is an integer of 1 to 8, and the amino acids constituting (Xaa)n may be one type of amino acid or two or more types of amino acids.

The disclosure relates to methods of prophylactic and therapeutic treatments of a Pneumocystis infection (i.e., an infection caused by Pneumocystis jirovecii) in a subject by administering to the subject a compound of any of formulas (1)-(111) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of a Pneumocystis spp. The methods of the disclosure can be useful in immunocompromised subjects.